

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

KaLy-Cell

RRID:SCR_003963

Type: Tool

Proper Citation

KaLy-Cell (RRID:SCR_003963)

Resource Information

URL: <http://www.kaly-cell.com/>

Proper Citation: KaLy-Cell (RRID:SCR_003963)

Description: Commercial organization that offers human and animal hepatocyte products as well as other products derived from liver tissue, kits and media. Services they offer include in vitro metabolism, in vitro toxicology and cell therapy.

Abbreviations: KaLy-Cell

Resource Type: commercial organization

Keywords: hepatocyte, in vitro, metabolism, toxicology, cell therapy, liver tissue, liver, cell culture, drug metabolism, drug transporter, enzyme induction, enzyme inhibition, drug, metabolism, transporter, enzyme, induction, inhibition, culture

Resource Name: KaLy-Cell

Resource ID: SCR_003963

Alternate IDs: nlx_158365

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260801T190228+0000

Ratings and Alerts

No rating or validation information has been found for KaLy-Cell.

No alerts have been found for KaLy-Cell.

Data and Source Information

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

van Riet S, et al. (2024) The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model. *Hepatology communications*, 8(3).

Botham J, et al. (2023) Species differences and human relevance of the toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors and a new approach method in vitro for investigation. *Archives of toxicology*, 97(4), 991.

Kashiwakura Y, et al. (2023) Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy. *Molecular therapy. Methods & clinical development*, 30, 502.

Piel I, et al. (2023) Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans. *European journal of drug metabolism and pharmacokinetics*, 48(4), 411.

Callegaro G, et al. (2021) The human hepatocyte TXG-MAPr: gene co-expression network modules to support mechanism-based risk assessment. *Archives of toxicology*, 95(12), 3745.

Leroy K, et al. (2021) Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines. *International journal of molecular sciences*, 22(22).

Leroy K, et al. (2021) Connexin-Based Channel Activity Is Not Specifically Altered by Hepatocarcinogenic Chemicals. *International journal of molecular sciences*, 22(21).

Mav D, et al. (2020) Utility of Extrapolating Human S1500+ Genes to the Whole Transcriptome: Tunicamycin Case Study. *Bioinformatics and biology insights*, 14, 1177932220952742.

Rubin K, et al. (2020) Pulmonary Metabolism of Substrates for Key Drug-Metabolizing Enzymes by Human Alveolar Type II Cells, Human and Rat Lung Microsomes, and the Isolated Perfused Rat Lung Model. *Pharmaceutics*, 12(2).

Mathieson T, et al. (2018) Systematic analysis of protein turnover in primary cells. *Nature communications*, 9(1), 689.

Gerisch M, et al. (2018) Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. *Cancer chemotherapy and pharmacology*, 81(1), 195.

Sison-Young RL, et al. (2017) A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. *Archives of*

toxicology, 91(3), 1385.

Ikeda Y, et al. (2017) Cholesterol attenuates cytoprotective effects of phosphatidylcholine against bile salts. *Scientific reports*, 7(1), 306.

Mennecozzi M, et al. (2015) Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro? *PloS one*, 10(4), e0122786.